Merck & Co., Inc. $MRK Stock Acquired by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC grew its stake in Merck & Co., Inc. (NYSE:MRK) by 8.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,158 shares of the company’s stock after acquiring an additional 3,593 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $6,853,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRK. Horizons Wealth Management acquired a new position in Merck & Co., Inc. during the 3rd quarter valued at about $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. in the second quarter worth $27,000. Graney & King LLC raised its stake in Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the period. Montgomery Financial Services LLC acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth about $41,000. Finally, Evergreen Advisors LLC bought a new position in Merck & Co., Inc. in the first quarter valued at approximately $43,000. Institutional investors own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $148.19 on Wednesday. The company has a 50 day moving average of $146.22 and a 200-day moving average of $129.67. The company has a market cap of $365.62 billion, a PE ratio of 118.55, a price-to-earnings-growth ratio of 6.64 and a beta of 0.21. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

Analyst Ratings Changes

A number of brokerages have recently commented on MRK. Cantor Fitzgerald boosted their price target on Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. UBS Group increased their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Royal Bank Of Canada cut their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research report on Monday, October 12th. Leerink Partners raised their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Finally, Barclays boosted their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.